CorMedix (CRMD) Common Equity (2010 - 2025)

CorMedix (CRMD) has 16 years of Common Equity data on file, last reported at $405.3 million in Q4 2025.

• For the quarter ending Q4 2025, Common Equity rose 378.76% year-over-year to $405.3 million; the trailing twelve-month figure through Dec 2025 stood at $405.3 million (up 378.76% YoY), and the FY2025 full-year result was $405.3 million, up 378.76% from the prior year.
• Common Equity advanced to $405.3 million in Q4 2025, from $374.1 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $405.3 million in Q4 2025 to a low of $46.2 million in Q2 2024.
• A 5-year average of $107.1 million and a median of $66.1 million in 2021 frame the typical range for Common Equity.
• Peak annual rise in Common Equity reached 294114.97% in 2021, while the deepest fall reached 63.9% in 2021.
• Tracing CRMD's Common Equity over 5 years: stood at $62.8 million in 2021, then retreated by 12.32% to $55.1 million in 2022, then advanced by 27.39% to $70.1 million in 2023, then rose by 20.69% to $84.7 million in 2024, then soared by 378.76% to $405.3 million in 2025.
• Business Quant data shows CRMD's Common Equity at $405.3 million in Q4 2025, $374.1 million in Q3 2025, and $220.6 million in Q2 2025.